Lipids & Metabolic

The authors of a new study in the Annals of Internal Medicine believe too many patients are being recommended statin therapy, and contend that current guidelines don’t fully consider the risks of the popular drugs.

A new expert consensus document from the American College of Cardiology singled out liraglutide and empagliflozin as the preferred drugs in their classes to reduce cardiovascular risk among patients with type 2 diabetes and atherosclerotic cardiovascular disease.

There were no adverse events related to atherosclerotic cardiovascular disease during a median 3.7 years of follow-up for 101 patients with familial hypercholesterolemia (FH) but a coronary artery calcium (CAC) score of zero, according to a study published Nov. 14 in JACC: Cardiovascular Imaging.

The FDA is backing a new “qualified health claim” that oils high in oleic acid can help improve cholesterol levels and protect against coronary heart disease, Commissioner Scott Gottlieb, MD, announced Nov. 19.

Diabetics who have transitioned to an employer-mandated, high-deductible insurance plan are significantly more likely to delay healthcare visits for macrovascular symptoms, diagnostic tests and procedures, researchers reported Nov. 20 in the Annals of Internal Medicine.

Just 45 minutes of chatting with a second-year medical student could improve disease management among patients with chronic conditions like hypertension, diabetes and chronic obstructive pulmonary disease (COPD), according to research published in the November issue of the Journal of the American Osteopathic Association.

An observational study of nearly 35,000 Scandinavian patients with type 2 diabetes (T2D) has found sodium-glucose cotransporter 2 (SGLT2) inhibitors, a class of prescription drugs approved by the FDA to lower blood sugar in adults with T2D, may almost double patients’ risks of lower limb amputation and diabetic ketoacidosis compared to glucagon-like peptide 1 (GLP1) receptor agonists.

A diabetic mother saddled with medical debt from type 1 diabetes (T1D) treatments and complications is highlighting the rising costs of insulin and T1D care in the United States, Forbes reports.

VITAL and REDUCE-IT—both highly anticipated trials revolving around the cardiovascular benefits of fish oil products—delivered mixed results at this year’s AHA Scientific Sessions in Chicago, with one trial observing few heart benefits from omega-3s while the other saw a 25 percent reduction in major cardiovascular events with a purified eicosapentaenoic acid product.

New cholesterol guidelines from the American Heart Association and the American College of Cardiology recommend adding ezetimibe and/or PCSK9 inhibitors to statin therapy for select high-risk patients, and also propose using coronary artery calcium (CAC) scoring as “a tiebreaker” to guide statin decisions for those at intermediate risk of atherosclerotic cardiovascular disease.

Up to a quarter of type 1 diabetes patients in England should have access to the Freestyle Libre, a flash glucose monitor that allows diabetics to check their blood sugar without the need for finger pricks. But a recent investigation by the BMJ has concluded that, in reality, just 3 to 5 percent of eligible patients have access to the potentially life-changing technology.

It’s not just what people eat—but when—that may influence their risk of developing prediabetes and high blood pressure, according to preliminary research scheduled to be presented Nov. 10 at the American Heart Association’s Scientific Sessions in Chicago.